Drug Profile

Immunoglobin E mediated allergic therapeutic - Merida Biosciences

Latest Information Update: 01 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

27 Feb 2026 Phase-0 for Immediate hypersensitivity (Early stage disease) (unspecified route), prior to February 2026 (Merida Biosciences pipeline, February 2026)
07 Jan 2026 Merida Biosciences has 3 patent pending applications, two for "Molecules for controlling autoimmune response" (WO 202 503 000 3A2) (WO 202 503 000 0A1) and one for "Molecules for controlling immune response" (WO 202 503 000 9A1) in the multiple countries worldwide prior to January 2026

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com